90% gross profit margin pharmaceutical companies appear!

Since the beginning of this year, 18 pharmaceutical companies have landed on A shares, of which 16 were listed in the first quarter
.
Judging from the performance in 2021, the gross profit margin of Rongchang Bio and Shouyao Holding both exceeded 90%, and only 4 lost money
.
At present, Fuyuan Medicine, Nuocheng Jianhua, etc.
have successfully attended the meeting, Yili Chuanning Biotechnology, Enwei Medicine, etc.
have inquired, and more than 40 pharmaceutical companies are on the way to IPO
.
It is worth noting that while new stocks have recently set off a "breaking wave", the phenomenon of winning investors abandoning their purchases also has an intensifying trend
.
In addition, the Central Commission for Discipline Inspection recently issued a document that it is necessary to close the market entrance and resolutely prevent the disorderly expansion of capital
.
Gross profit margin of over 90% is amazing! 18 pharmaceutical companies from Rongchang and Shouyao "assembled" A-shares.
This year's A-share-listed pharmaceutical companies' performance in 2021 The top 16 listed companies listed in the first quarter, and the number increased by 5 compared with the first quarter of last year
.
Judging from the performance in 2021, the gross profit margin of Rongchang Bio and Shouyao Holding both exceeded 90%, and only 4 lost money
.
Rongchang Bio's revenue was 1.
426 billion yuan, a year-on-year increase of more than 400 times, and its net profit was 276 million yuan, a year-on-year increase of 139.
59%
.
Regarding the future development strategy, Rongchang Bio said that the company is committed to the discovery, development, production and commercialization of innovative biological drugs for the treatment of autoimmune diseases, tumors, ophthalmology and other major diseases, so as to meet the unmet clinical needs of global patients.
In order to realize the corporate vision of "becoming China's leading and world-class biopharmaceutical company"
.
In the next 3-5 years, the company will rapidly promote the pipeline development and commercialization process, focus on the approval and commercialization of core products; implement the international development strategy; expand production capacity to meet the needs of global clinical research and commercialization
.
Entering April, Tianyi Medical and Haichuang Pharmaceutical were successfully listed, and Yaokang Biotech has won the contract and paid for it, and it is very close to the official listing.

.
It is worth noting that there has been a "breaking wave" of new shares recently.
According to statistics, last week (April 11-15), a total of 8 new A-shares were listed, of which 5 broke, and more than 90 new shares were listed this year.
More than half of them broke
.
In addition, the phenomenon of winning investors abandoning their purchases also has an intensifying trend
.
Analysts in the industry pointed out that the frequent breakouts of new shares are due to factors such as market fluctuations and the comprehensive promotion of the registration system.
The supply of new shares has increased and the scarcity has declined.
The once "invincible myth" has become normalized, and the market structure is gradually being reshaped
.
On the other hand, IPO abandonment is constantly breaking new records.
The new price inquiry regulations introduced last year have pushed up the pricing of IPOs to a certain extent, which has led to a decline in the revenue from new listings.
Funds participating in new listings are more cautious.
Language, but also a test of professionalism and understanding of the industry
.
Fuyuan, Enwei.
.
.
More than 40 IPOs are on the way for pharmaceutical companies to issue their first application/registration review information.
At present, Fuyuan Pharmaceutical, Nuocheng Jianhua, etc.
have successfully attended the meeting, Yili Chuanning Biotechnology, Enwei Pharmaceutical, etc.
have inquired, more than IPOs of 40 pharmaceutical companies are on the way
.
In terms of registration places, the number of enterprises in Shanghai, Guangdong, Beijing, and Jiangsu ranks among the top four
.
Fuyuan Medicine will meet! 8 first imitations, 22 reviewed varieties, and 5 innovative drugs under development.
Fuyuan Pharmaceutical is mainly engaged in the research and development, production and sales of pharmaceutical preparations and medical devices.
Its products cover cardiovascular system, digestive system, and mental and nervous system.
, gynecological drugs, humidification and oxygen absorption devices and other markets, and build a business system of "pharmaceutical preparations + medical devices"
.
In the field of pharmaceutical preparations, Fuyuan Pharmaceutical has 8 domestic first imitation products, and 22 varieties (26 product specifications) have been reviewed
.
In the first five batches, the company's paroxetine hydrochloride tablets, olmesartan medoxomil tablets, montelukast sodium chewable tablets, trimetazidine hydrochloride tablets, gliclazide sustained-release tablets, repaglinide tablets, Eight varieties including misartan tablets and venlafaxine hydrochloride sustained-release capsules won the bid
.
In addition, it also has 23 generic drug preparations, 5 innovative drugs and other research projects
.
In the future, the company will continue to consolidate the main business on the basis of strengthening research and development, implement the "combination of imitation and innovation" strategy, continuously improve the company's product competitiveness and market share, and enhance the company's profitability
.
Enwei Medicine holds the best-selling traditional Chinese medicine for gynecological inflammation, and 17 exclusive varieties account for more than 50% of its revenue.
Enwei Medicine focuses on gynecological products, pediatric medicines, and respiratory medicines.
, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid and other 17 exclusive varieties, and the total sales revenue of exclusive varieties accounted for more than 50% of the main business income
.
The company has been deeply engaged in the field of gynecological products for many years.
According to the data of Minet, in recent years, the market share of Jieeryin Lotion, the core product of Enwei Medicine, has ranked first in the field of Chinese patent medicine for gynecological inflammation in Chinese urban physical pharmacies, and it is expected to stabilize again in 2021.
climb
.
In addition to the external gynecological lotion, Enwei Medicine has continuously developed formulations such as ointments, suppositories, effervescent tablets, and disinfection products such as antibacterial lotions, and plans to develop a series of gynecological internal medicine products through independent research and development, joint research and development, and purchase of varieties.
Continue to maintain and further enhance the company's leading position in the field of domestic gynecological products
.
While focusing on gynecological products, the company continuously expands product extension by leveraging the advantages of brands and sales channels, actively develops medicines for pediatrics and respiratory system, and forms a diversified product covering the fields of reproductive system, digestive system, respiratory system and supplements.
product group
.
The Central Commission for Discipline Inspection rarely speaks! Close the market entrance and resolutely prevent the disorderly expansion of capital.
Recently, the Central Commission for Discipline Inspection issued a document stating that due to various factors such as the epidemic, the current operation of the capital market is facing many uncertainties, and there is great pressure on stable operation
.
In order to maintain the healthy and stable development of economy and finance, the Disciplinary Inspection and Supervision Team of the Central Commission for Discipline Inspection of the China Securities Regulatory Commission, based on its functions and responsibilities, continues to strengthen political supervision, promote the strengthening of securities supervision and law enforcement with strong supervision, and effectively prevent and resolve capital market risks
.
The article pointed out that this year's government work report lists the full implementation of the stock issuance registration system as one of the tasks for 2022.

.
In order to ensure the smooth progress of the reform, the Disciplinary Inspection and Supervision Team stationed at the CSRC will focus on supervising the performance of supervisory responsibilities by the CSRC Party Committee and the Shanghai and Shenzhen Stock Exchange Party Committees.
On-site inspection
.
In view of the weak links found in daily supervision, we will submit written supervision opinions to the Party Committee of the China Securities Regulatory Commission and the Party Committee of the Shanghai and Shenzhen Stock Exchanges to urge the market entry gates to be well controlled and resolutely prevent the disorderly expansion of capital
.
Source: Oriental Fortune.
com, Minet.
com database, the official website of the Central Commission for Discipline Inspection, etc.
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database covers 297 cities and above nationwide physical pharmacies (excluding county and rural physical pharmacies).
An enlarged version of the city's brick-and-mortar pharmacy database for continuous monitoring
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of the close of April 15th.
If there are any omissions, please correct me!